182 related articles for article (PubMed ID: 26456735)
1. Development of Potent and Selective Tissue Transglutaminase Inhibitors: Their Effect on TG2 Function and Application in Pathological Conditions.
Badarau E; Wang Z; Rathbone DL; Costanzi A; Thibault T; Murdoch CE; El Alaoui S; Bartkeviciute M; Griffin M
Chem Biol; 2015 Oct; 22(10):1347-61. PubMed ID: 26456735
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
Chrobok NL; Bol JGJM; Jongenelen CA; Brevé JJP; El Alaoui S; Wilhelmus MMM; Drukarch B; van Dam AM
PLoS One; 2018; 13(4):e0196433. PubMed ID: 29689097
[TBL] [Abstract][Full Text] [Related]
3. Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor.
Wang Z; Stuckey DJ; Murdoch CE; Camelliti P; Lip GYH; Griffin M
Cell Death Dis; 2018 Apr; 9(6):613. PubMed ID: 29795262
[TBL] [Abstract][Full Text] [Related]
4. Syndecan-4 knockout leads to reduced extracellular transglutaminase-2 and protects against tubulointerstitial fibrosis.
Scarpellini A; Huang L; Burhan I; Schroeder N; Funck M; Johnson TS; Verderio EA
J Am Soc Nephrol; 2014 May; 25(5):1013-27. PubMed ID: 24357671
[TBL] [Abstract][Full Text] [Related]
5. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
Yuan L; Siegel M; Choi K; Khosla C; Miller CR; Jackson EN; Piwnica-Worms D; Rich KM
Oncogene; 2007 Apr; 26(18):2563-73. PubMed ID: 17099729
[TBL] [Abstract][Full Text] [Related]
6. Tissue Transglutaminase contributes to experimental multiple sclerosis pathogenesis and clinical outcome by promoting macrophage migration.
van Strien ME; de Vries HE; Chrobok NL; Bol JGJM; Breve JJP; van der Pol SMP; Kooij G; van Buul JD; Karpuj M; Steinman L; Wilhelmus MM; Sestito C; Drukarch B; Van Dam AM
Brain Behav Immun; 2015 Nov; 50():141-154. PubMed ID: 26133787
[TBL] [Abstract][Full Text] [Related]
7. Photolabeling of tissue transglutaminase reveals the binding mode of potent cinnamoyl inhibitors.
Pardin C; Roy I; Chica RA; Bonneil E; Thibault P; Lubell WD; Pelletier JN; Keillor JW
Biochemistry; 2009 Apr; 48(15):3346-53. PubMed ID: 19271761
[TBL] [Abstract][Full Text] [Related]
8. Activation of transglutaminase type 2 for aortic wall protection in a rat abdominal aortic aneurysm formation.
Munezane T; Hasegawa T; Suritala ; Tanaka A; Okada K; Okita Y
J Vasc Surg; 2010 Oct; 52(4):967-74. PubMed ID: 20615646
[TBL] [Abstract][Full Text] [Related]
9. A novel extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis.
Wang Z; Perez M; Caja S; Melino G; Johnson TS; Lindfors K; Griffin M
Cell Death Dis; 2013 Sep; 4(9):e808. PubMed ID: 24052076
[TBL] [Abstract][Full Text] [Related]
10. Activation and inhibition of transglutaminase 2 in mice.
Dafik L; Albertelli M; Stamnaes J; Sollid LM; Khosla C
PLoS One; 2012; 7(2):e30642. PubMed ID: 22319575
[TBL] [Abstract][Full Text] [Related]
11. An unprecedented dual antagonist and agonist of human Transglutaminase 2.
Yi MC; Palanski BA; Quintero SA; Plugis NM; Khosla C
Bioorg Med Chem Lett; 2015 Nov; 25(21):4922-4926. PubMed ID: 26004580
[TBL] [Abstract][Full Text] [Related]
12. Heparan sulfate proteoglycans are receptors for the cell-surface trafficking and biological activity of transglutaminase-2.
Scarpellini A; Germack R; Lortat-Jacob H; Muramatsu T; Billett E; Johnson T; Verderio EA
J Biol Chem; 2009 Jul; 284(27):18411-23. PubMed ID: 19398782
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of tissue transglutaminase.
Keillor JW; Apperley KY; Akbar A
Trends Pharmacol Sci; 2015 Jan; 36(1):32-40. PubMed ID: 25500711
[TBL] [Abstract][Full Text] [Related]
14. Transglutaminase 2: a novel therapeutic target for idiopathic pulmonary fibrosis using selective small molecule inhibitors.
Fell S; Wang Z; Blanchard A; Nanthakumar C; Griffin M
Amino Acids; 2021 Feb; 53(2):205-217. PubMed ID: 33474654
[TBL] [Abstract][Full Text] [Related]
15. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors.
Song M; Hwang H; Im CY; Kim SY
J Med Chem; 2017 Jan; 60(2):554-567. PubMed ID: 28122456
[TBL] [Abstract][Full Text] [Related]
16. Characterization of heparin-binding site of tissue transglutaminase: its importance in cell surface targeting, matrix deposition, and cell signaling.
Wang Z; Collighan RJ; Pytel K; Rathbone DL; Li X; Griffin M
J Biol Chem; 2012 Apr; 287(16):13063-83. PubMed ID: 22298777
[TBL] [Abstract][Full Text] [Related]
17. β
Vyas FS; Nelson CP; Freeman F; Boocock DJ; Hargreaves AJ; Dickenson JM
Eur J Pharmacol; 2017 Oct; 813():105-121. PubMed ID: 28754379
[TBL] [Abstract][Full Text] [Related]
18. A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors.
Schaertl S; Prime M; Wityak J; Dominguez C; Munoz-Sanjuan I; Pacifici RE; Courtney S; Scheel A; Macdonald D
J Biomol Screen; 2010 Jun; 15(5):478-87. PubMed ID: 20395409
[TBL] [Abstract][Full Text] [Related]
19. The role of tissue transglutaminase (TG2) in regulating the tumour progression of the mouse colon carcinoma CT26.
Kotsakis P; Wang Z; Collighan RJ; Griffin M
Amino Acids; 2011 Oct; 41(4):909-21. PubMed ID: 21046178
[TBL] [Abstract][Full Text] [Related]
20. Transglutaminase 2 strongly binds to an extracellular matrix component other than fibronectin via its second C-terminal beta-barrel domain.
Stamnaes J; Cardoso I; Iversen R; Sollid LM
FEBS J; 2016 Nov; 283(21):3994-4010. PubMed ID: 27685605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
